The country has also made significant inroads in biologics manufacturing, with Amgen, Baxter, GlaxoSmithKline, Lonza, Novartis, and Roche announcing their investments to set up major biologics facilities that amount to S$2.4 billion in capital expenditure. In less than five years, Singapore has become home to eight biologics manufacturing facilities. To date, all pharmaceutical manufacturing facilities that have commenced commercial operations have received validation from international regulators such as the US Food and Drug Administration, the European Medicines Agency and the Japan Pharmaceuticals and Medical Devices Agency. Similarly, Singapore is a trusted base for companies to manufacture complex and high-quality instruments and medical devices for global markets. In 2013, Edwards more than doubled the size of its manufacturing facility to expand the production of Edwards’ world-leading class III Carpentier-Edwards PERIMOUNT tissue heart valves and the Edwards SAPIEN XT transcatheter heart valves. In 2012, Life Technologies announced that it had set up a Global Instrument Centre of Excellence in Singapore, which will design and manufacture next-generation products such as sequencing and mole-cular diagnostic instruments.
Healthcare Industries in Singapore
HOME TO DRIVE EXPANSION IN ASIA Many companies use Singapore as a base for their business activities. Currently, global companies and Asian enterprises alike are already using Singapore as a beachhead in Asia. This includes eight of the top 10 pharmaceutical and all of the top 10 medical technology companies, which have their regional headquarters in Singapore, from which to drive business expansion in Asia. These companies leverage the city-state’s global connectivity and its workforce’s intimate understanding of regional markets, to identify new strategic business opportunities, accelerate new product introduction, as well as manage regional clinical trials and supply chains in Asia. For example, Medtronic has built upon its presence in Singapore and opened its global Centre of Excellence for Business Model Innovation in August 2013. This new facility is responsible for designing, testing and scaling new business models for the rapidly growing emerging markets across Asia. Moving forward, in order to better access emerging markets in the region, companies have to relook global operational structures across R&D, manufacturing and commercial. We believe that having an integrated location in Singapore with commercial, R&D and manufacturing activities will allow key company decision
makers and commercial leads to respond and adapt quickly to market needs through synergies created between critical elements within each function. For example, the commercial teams can channel market insights and demand sensing information more quickly to their supply chain, R&D and clinical development teams so that there is a shorter lag time. At present, top biomedical companies carry out essential business activities spanning regional headquarters, R&D and manufacturing activities in Singapore. At the same time, regional pharmaceutical players such as Japan-based Chugai Pharmabody Research and Indonesia based PT Kalbe Farma have increased and strengthened their business and R&D activities in Singapore. Beyond oversight on business activities, companies are increasingly looking at Singapore for financing solutions to ride the growth of Asia. Lonza Group, one of the world’s leading biopharmaceutical contract manufacturers, announced its secondary listing of the Singapore stock exchange to harness support from regio-nal investors. Companies can draw on Singapore’s networks, talent, pro-business environment and financing opportunities to strengthen and grow their business in Asia. F RIGHT Kevin Lai, Director of Biomedical Sciences, Economic Development Board
January 2014 issue of Focus magazine by the French Chamber of Commerce in Singapore